vs
GYRE THERAPEUTICS, INC.（GYRE）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
GYRE THERAPEUTICS, INC.的季度营收约是Rumble Inc.的1.4倍（$37.2M vs $27.1M），GYRE THERAPEUTICS, INC.净利率更高（-3.7% vs -120.8%，领先117.1%），GYRE THERAPEUTICS, INC.同比增速更快（33.4% vs -10.5%），GYRE THERAPEUTICS, INC.自由现金流更多（$-5.8M vs $-31.7M），过去两年GYRE THERAPEUTICS, INC.的营收复合增速更高（17.0% vs 15.2%）
GYRE Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性血液系统恶性肿瘤和实体瘤的新型靶向疗法，聚焦精准肿瘤学领域以满足未被满足的患者医疗需求，主要在北美地区开展业务。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
GYRE vs RUM — 直观对比
营收规模更大
GYRE
是对方的1.4倍
$27.1M
营收增速更快
GYRE
高出43.9%
-10.5%
净利率更高
GYRE
高出117.1%
-120.8%
自由现金流更多
GYRE
多$25.9M
$-31.7M
两年增速更快
GYRE
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $27.1M |
| 净利润 | $-1.4M | $-32.7M |
| 毛利率 | 95.3% | 5.5% |
| 营业利润率 | 0.3% | -131.1% |
| 净利率 | -3.7% | -120.8% |
| 营收同比 | 33.4% | -10.5% |
| 净利润同比 | -340.1% | 86.2% |
| 每股收益（稀释后） | $-0.01 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GYRERUM
| Q4 25 | $37.2M | $27.1M | ||
| Q3 25 | $30.6M | $24.8M | ||
| Q2 25 | $26.8M | — | ||
| Q1 25 | $22.1M | $23.7M | ||
| Q4 24 | $27.9M | $30.2M | ||
| Q3 24 | $25.5M | $25.1M | ||
| Q2 24 | $25.2M | $22.5M | ||
| Q1 24 | $27.2M | $17.7M |
净利润GYRERUM
| Q4 25 | $-1.4M | $-32.7M | ||
| Q3 25 | $5.9M | $-16.3M | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $3.7M | $-2.7M | ||
| Q4 24 | $569.0K | $-236.8M | ||
| Q3 24 | $2.9M | $-31.5M | ||
| Q2 24 | $4.5M | $-26.8M | ||
| Q1 24 | $9.9M | $-43.3M |
毛利率GYRERUM
| Q4 25 | 95.3% | 5.5% | ||
| Q3 25 | 94.7% | -1.8% | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | -26.7% | ||
| Q4 24 | 95.8% | -14.2% | ||
| Q3 24 | 96.2% | -45.4% | ||
| Q2 24 | 96.9% | -58.8% | ||
| Q1 24 | 96.4% | -79.5% |
营业利润率GYRERUM
| Q4 25 | 0.3% | -131.1% | ||
| Q3 25 | 22.7% | -113.6% | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 10.3% | -153.5% | ||
| Q4 24 | 2.4% | -80.1% | ||
| Q3 24 | 16.6% | -131.0% | ||
| Q2 24 | 12.7% | -172.7% | ||
| Q1 24 | 29.7% | -197.4% |
净利率GYRERUM
| Q4 25 | -3.7% | -120.8% | ||
| Q3 25 | 19.4% | -65.7% | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 16.9% | -11.2% | ||
| Q4 24 | 2.0% | -783.2% | ||
| Q3 24 | 11.2% | -125.9% | ||
| Q2 24 | 18.0% | -119.2% | ||
| Q1 24 | 36.6% | -244.1% |
每股收益（稀释后）GYRERUM
| Q4 25 | $-0.01 | $-0.13 | ||
| Q3 25 | $0.03 | $-0.06 | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | $-0.01 | ||
| Q4 24 | $0.00 | $-1.17 | ||
| Q3 24 | $0.01 | $-0.15 | ||
| Q2 24 | $0.01 | $-0.13 | ||
| Q1 24 | $0.03 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $106.0M | $274.8M |
| 总资产 | $166.1M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GYRERUM
| Q4 25 | $52.4M | $237.9M | ||
| Q3 25 | $60.0M | $269.8M | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | $301.3M | ||
| Q4 24 | $26.7M | $114.0M | ||
| Q3 24 | $25.1M | $132.0M | ||
| Q2 24 | $25.1M | $154.2M | ||
| Q1 24 | $37.4M | $183.8M |
股东权益GYRERUM
| Q4 25 | $106.0M | $274.8M | ||
| Q3 25 | $101.9M | $302.2M | ||
| Q2 25 | $92.0M | — | ||
| Q1 25 | $68.1M | $339.6M | ||
| Q4 24 | $63.3M | $-63.1M | ||
| Q3 24 | $63.2M | $166.1M | ||
| Q2 24 | $60.4M | $192.7M | ||
| Q1 24 | $56.6M | $210.7M |
总资产GYRERUM
| Q4 25 | $166.1M | $336.8M | ||
| Q3 25 | $159.4M | $367.2M | ||
| Q2 25 | $152.6M | — | ||
| Q1 25 | $129.8M | $391.1M | ||
| Q4 24 | $125.4M | $195.3M | ||
| Q3 24 | $125.2M | $217.2M | ||
| Q2 24 | $120.9M | $243.2M | ||
| Q1 24 | $122.0M | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $-31.7M |
| 自由现金流率自由现金流/营收 | -15.5% | -117.2% |
| 资本支出强度资本支出/营收 | 0.4% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-180.0K | $-70.8M |
8季度趋势，按日历期对齐
经营现金流GYRERUM
| Q4 25 | $-5.6M | $-29.4M | ||
| Q3 25 | $4.7M | $-10.6M | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $-129.0K | $-14.5M | ||
| Q4 24 | $-2.8M | $-12.4M | ||
| Q3 24 | $1.7M | $-19.1M | ||
| Q2 24 | $-5.5M | $-21.7M | ||
| Q1 24 | $2.9M | $-33.9M |
自由现金流GYRERUM
| Q4 25 | $-5.8M | $-31.7M | ||
| Q3 25 | $4.0M | $-12.0M | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | $-14.6M | ||
| Q4 24 | $-2.8M | $-12.4M | ||
| Q3 24 | $1.0M | $-19.9M | ||
| Q2 24 | $-6.9M | $-23.1M | ||
| Q1 24 | $2.7M | $-34.3M |
自由现金流率GYRERUM
| Q4 25 | -15.5% | -117.2% | ||
| Q3 25 | 13.1% | -48.6% | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | -61.7% | ||
| Q4 24 | -10.1% | -40.9% | ||
| Q3 24 | 4.1% | -79.5% | ||
| Q2 24 | -27.5% | -102.8% | ||
| Q1 24 | 9.8% | -193.3% |
资本支出强度GYRERUM
| Q4 25 | 0.4% | 8.5% | ||
| Q3 25 | 2.2% | 5.7% | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 2.7% | 3.4% | ||
| Q2 24 | 5.8% | 6.1% | ||
| Q1 24 | 0.9% | 2.4% |
现金转化率GYRERUM
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GYRE
暂无分部数据
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
